XENE
Xenon Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$35.77
+1.22%Price chart
Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26
Key dataOct 26, 2026
Open$35.34
From 52W high−49.59%
Volume720335.00
Market cap$3.46B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 26, 2026
Open
$35.34
From 52W high
−49.59%
Volume
720335.00
Market cap
$3.46B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.1x
P/E (TTM)
—
RSI (14)
34.6
MomentumView details →
1D Return
+1.22%
YTD Return
−20.38%
SummaryUpdated Jun 1, 2026
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is a clinical-stage biopharmaceutical company founded in 1996 and headquartered in Burnaby, Canada. The company specializes in developing neurological therapeutics by targeting ion channels, particularly potassium and sodium channels in the brain. Xenon has built its expertise around understanding the genetic basis of neurological disorders and translating these insights into targeted drug therapies. The company went public in 2014 and has since advanced multiple drug candidates through clinical trials, with its lead program <b>azetukalner</b> (XEN1101) currently in Phase 3 trials for epilepsy and depression.
Similar companies
Latest newsMore news →
Xenon Pharmaceuticals director, president and CEO Ian Mortimer bought 30,000 company shares for $1,121,400 on September 30, 2026, per a Form 4 filed with the SEC.26d agoSueWallSt notified investors of a pending investigation into Xenon Pharmaceuticals following the company's disclosure of an enrollment pause in its Phase 3 depression trials for azetukalner, which sent XENE shares down as much as 27.6%.34d agoWolf Popper LLP announced an investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. common stock.35d ago